Downregulation of insulin-like growth factorbinding protein 7 in cisplatin-resistant non-small cell lung cancer

Cancer Biology and Therapy

Volumn 13, Issue 3, 2012, Pages 148-155

  Okamura, Jun ^a,b   Huang, Yiping ^a   Moon, David ^a   Brait, Mariana ^a   Chang, Xiaofei ^a   Kim, Myoung Sook ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin resistance; Erk; Human xenografts; IGFBP7; MKP3; NSCLC; Stat3

Indexed keywords

CISPLATIN; DUAL SPECIFICITY PHOSPHATASE 6; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 7; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DUAL SPECIFICITY PHOSPHATASE 6; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863171538     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.3.18695     Document Type: Article

References (32)

1. Sánchez-Pérez I, Martínez-Gomariz M, Williams D, Keyse SM, Perona R. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 2000; 19:5142-52; PMID:11064451; http://dx.doi.org/10.1038/sj.onc.1203887
2. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. Essential roles of IGFBP-3 and IGFBPrP1 in breast cancer. Eur J Cancer 2005; 41:1515- 27; PMID:15979304; http://dx.doi.org/10.1016/j.ejca. 2005.04.023
3. Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, et al. IGFBP7 is a p53 responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 2010; 31:342-9; PMID:19638426; http://dx.doi.org/10. 1093/carcin/bgp179
4. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132:363-74; PMID: 18267069; http://dx.doi.org/10. 1016/j.cell.2007.12. 032
5. Wajapeyee N, Kapoor V, Mahalingam M, Green MR. Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol Cancer Ther 2009; 8:3009-14; PMID:19861408; http://dx.doi.org/ 10.1158/1535-7163.MCT-09-0470
6. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS ONE 2009; 4:e8357; PMID:20027224; http://dx.doi.org/10.1371/journal. pone.0008357
7. Tomimaru Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, et al. IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer 2011. In press. PMID:21328580; http://dx.doi. org/10.1002/ijc.25994
8. Nousbeck J, Sarig O, Avidan N, Indelman M, Bergman R, Ramon M, et al. Insulin-like growth factor-binding protein 7 regulates keratinocyte proliferation, differentiation and apoptosis. J Invest Dermatol 2010; 130:378-87; PMID:19710688; http://dx.doi.org/10. 1038/jid.2009.265
9. Smith P, Nicholson LJ, Syed N, Payne A, Hiller L, Garrone O, et al. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin Cancer Res 2007; 13:4061-8; PMID: 17634530; http://dx.doi.org/10.1158/1078-0432.CCR-06-3052
10. Tomimaru Y, Eguchi H, Wada H, Noda T, Murakami M, Kobayashi S, et al. Insulin-like growth factorbinding protein 7 alters the sensitivity to interferonbased anticancer therapy in hepatocellular carcinoma cells. Br J Cancer 2010; 102:1483-90; PMID: 20407444; http://dx.doi.org/10.1038/sj.bjc. 6605669
11. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000; 14:6-16; PMID:10627275
12. Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal 2004; 16:769-79; PMID:15115656; http://dx.doi.org/10.1016/j.cellsig. 2003.12.008
13. Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, et al. MKP1/ CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006; 25:3335-45; PMID:16462770; http://dx.doi. org/10.1038/sj.onc.1209364
14. Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, et al. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett 2009; 286:206-16; PMID:19553005; http://dx.doi.org/10.1016/j.canlet.2009.05.029
15. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, et al. Elevated expression of mitogenactivated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 2006; 66:5950-9; PMID:16740736; http://dx.doi.org/10. 1158/0008-5472.CAN-05-3243
16. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994; 369:156-60; PMID:8177321; http://dx.doi.org/10.1038/369156a0
17. Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 2010; 23:671-6; PMID: 20127005
18. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Kuppusamy P. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 2009; 125:2198-204; PMID:19623660; http://dx.doi. org/10.1002/ijc.24601
19. Ikuta K, Takemura K, Kihara M, Nishimura M, Ueda N, Naito S, et al. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol Rep 2005; 13:217-22; PMID:15643501
20. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-21; PMID:8197455; http://dx.doi.org/10.1126/science. 8197455
21. Ihle JN. Cytokine receptor signalling. Nature 1995; 377:591-4; PMID:7566171; http://dx.doi.org/10.1038/377591a0
22. Leppä S, Saffrich R, Ansorge W, Bohmann D. Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. EMBO J 1998; 17:4404-13; PMID:9687508; http://dx.doi.org/10.1093/emboj/17.15.4404
23. Shi M, Liu D, Duan H, Han C, Wei B, Qian L, et al. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Mol Cancer 2010; 9:269; PMID:20939893
24. Gorelik B, Ziv I, Shohat R, Wick M, Hankins WD, Sidransky D, et al. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 2008; 68:9033-40; PMID:18974149; http://dx.doi.org/10.1158/0008- 5472.CAN-08-1723
25. Chen Y, Cui T, Knösel T, Yang L, Zöller K, Petersen I. IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. Lung Cancer 2011; 73:38-44; PMID:21095038; http://dx.doi.org/ 10.1016/j.lungcan.2010.10.015
26. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 2010; 70:2870-9; PMID:20215521; http://dx.doi.org/10. 1158/0008-5472.CAN-09-3427
27. Messina S, Frati L, Leonetti C, Zuchegna C, Di Zazzo E, Calogero A, et al. Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene 2011; 30:3813-20; PMID: 21499306; http://dx.doi.org/10. 1038/onc.2011.99
28. Bermudez O, Jouandin P, Rottier J, Bourcier C, Pagès G, Gimond C. Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia. J Cell Physiol 2011; 226:276-84; PMID: 20665674; http://dx.doi.org/10.1002/jcp.22339
29. Park JC, Chae YK, Son CH, Kim MS, Lee J, Ostrow K, et al. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun 2008; 365:221-6; PMID: 17980147; http://dx.doi.org/ 10.1016/j.bbrc.2007.10.144
30. Caney C, Bulmer JT, Singh G, Lukka H, Rainbow AJ. Pre-exposure of human squamous carcinoma cells to low-doses of gamma-rays leads to an increased resistance to subsequent low-dose cisplatin treatment. Int J Radiat Biol 1999; 75:963-72; PMID:10465362; http:// dx.doi.org/10.1080/095530099139728
31. Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM. Characterisation of high-level cisplatinresistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer 1995; 71:676-83; PMID:7710928; http://dx.doi.org/10.1038/bjc.1995.134
32. Kim MS, Chang X, LeBron C, Nagpal JK, Lee J, Huang Y, et al. Neurofilament heavy polypeptide regulates the Akt-beta-catenin pathway in human esophageal squamous cell carcinoma. PLoS ONE 2010; 5:e9003; PMID:20140245; http://dx.doi.org/10.1371/journal.pone.0009003